The role of pulmonary arterial stiffness in COPD
Weir-McCall, Jonathan R.; Struthers, Allan D.; Lipworth, Brian J.; Houston, J. Graeme

Published in:
Respiratory Medicine

DOI:
10.1016/j.rmed.2015.06.005

Publication date:
2015

Licence:
CC BY

Document Version
Publisher's PDF, also known as Version of record

Link to publication in Discovery Research Portal

Citation for published version (APA):
Weir-McCall, J. R., Struthers, A. D., Lipworth, B. J., & Houston, J. G. (2015). The role of pulmonary arterial stiffness in COPD. Respiratory Medicine, 109(11), 1381-1390. https://doi.org/10.1016/j.rmed.2015.06.005
1. Introduction

COPD is the second most common cause of pulmonary hypertension after left sided heart disease [1]. Pulmonary hypertension refers to a combination of features that suggests PA stiffness as a promising biomarker for early detection of pulmonary vascular disease, and to play a role in right ventricular failure in COPD. Early detection would open this up as a potential therapeutic target before end stage arterial remodelling occurs. The compliance of the pulmonary artery (PA) is a key component in decoupling the right ventricle from the pulmonary bed, allowing the right ventricle to work at maximum efficiency and protecting the microcirculation from large pressure gradients. PA stiffness increases with the severity of COPD, and correlates well with the presence of exercise induced pulmonary hypertension. A curvilinear relationship exists between PA distensibility and mPAP and pulmonary vascular resistance (PVR) with marked loss of distensibility before a rapid rise in mPAP and PVR occurs with resultant right ventricular failure. This combination of features suggests PA stiffness as a promising biomarker for early detection of pulmonary vascular disease, and to play a role in right ventricular failure in COPD. Early detection would open this up as a potential therapeutic target before end stage arterial remodelling occurs.

COPD is the second most common cause of pulmonary hypertension, and is a common complication of severe COPD with significant implications for both quality of life and mortality. However, the use of a rigid diagnostic threshold of a mean pulmonary arterial pressure (mPAP) of ≥25mHg when considering the impact of the pulmonary vasculature on symptoms and disease is misleading. Even minimal exertion causes oxygen desaturation and elevations in mPAP, with right ventricular hypertrophy and dilatation present in patients with mild to moderate COPD with pressures below the threshold for diagnosis of pulmonary hypertension. This has significant implications, with right ventricular dysfunction associated with poorer exercise capability and increased mortality independent of pulmonary function tests. The compliance of the pulmonary artery (PA) is a key component in decoupling the right ventricle from the pulmonary bed, allowing the right ventricle to work at maximum efficiency and protecting the microcirculation from large pressure gradients. PA stiffness increases with the severity of COPD, and correlates well with the presence of exercise induced pulmonary hypertension. A curvilinear relationship exists between PA distensibility and mPAP and pulmonary vascular resistance (PVR) with marked loss of distensibility before a rapid rise in mPAP and PVR occurs with resultant right ventricular failure. This combination of features suggests PA stiffness as a promising biomarker for early detection of pulmonary vascular disease, and to play a role in right ventricular failure in COPD. Early detection would open this up as a potential therapeutic target before end stage arterial remodelling occurs. © 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
comparison to other causes of pulmonary hypertension the pulmonary pressure elevations are modest, however survival is poor and correlates better with the pulmonary pressures and pulmonary vascular resistance than with the severity of airflow obstruction [5–8].

Pulmonary hypertension is defined as a mean pulmonary arterial pressure (mPAP) greater than or equal to 25 mmHg at rest [9]. However: Pulmonary vascular changes occur in mild COPD before pulmonary hypertension occurs [10]; Right ventricular dysfunction has been observed in normoxaemic COPD patients with normal pulmonary arterial pressures [11]; and right ventricular hypertrophy is one of the earliest cardiac changes and is present even in mild COPD [12–14]. Additionally in both mice and guinea pig models, vascular remodelling occurs even before the onset of emphysema [15–17]. The notion of an elevated rest pressure as a cut-off is also restrictive in evaluating the role of the pulmonary arteries and right heart as even minimal exertion causes marked elevations in mPAP and oxygen desaturation in COPD, with exercise induced pulmonary hypertension present in 35%–58% of patients with normoxaemia or mild hypoxia [3,18–20].

Therefore the pulmonary hypertension model, whereby right ventricular failure occurs once pulmonary hypertension exists, is a misnomer, and an alternate should be considered - the right ventriculo-arterial model.

1.1. Vascular changes

Vascular remodelling within COPD develops secondary to intimal hyperplasia, with muscularisation of the arterioles and with rather little change in the tunica media [21,22]. This hyperplasia is induced by proliferation of smooth muscle cells and the deposition of elastic and collagen fibres [23,24]. Originally hypoxia was held to be the driving force behind this remodelling, however similar arterial changes are present in smokers with and without COPD, and arterial changes can be observed in mild COPD when hypoxia is yet to develop [10,23,25]. The vascular remodelling in COPD is most likely due to endothelial dysfunction and apoptosis which in turn causes remodelling, capillary loss and small vessel thrombosis [26]. This is likely due to a combination of local inflammatory mediators released from the endothelial dysfunction in the adjacent pulmonary parenchyma, and direct effects from the inhaled cigarette smoke on the vascular endothelium [24,26]. However an experimental study by Ferrer et al. in guinea pig models shows hypoxia still plays a contributory role, as a hypoxic environment after cigarette exposure induced significantly greater changes in pulmonary arterial pressures and pulmonary vascular remodelling than cigarette smoking or hypoxia alone [17]. More recently the pulmonary vascular sympathetic nerves which control the pulmonary baroreceptor reflex originating at the pulmonary trunk has been proposed to be of significant importance in the development of pulmonary arterial hypertension [27]. This is evidenced by a rise in pulmonary arterial pressures and pulmonary vascular resistance (PVR) induced by stretching the branch pulmonary arteries [27–30]. In a single study by Chen et al. [31] on 21 patients with significant pulmonary hypertension despite maximum medical therapy, intravascular pulmonary artery denervation with cessation of medical therapy resulted in significant improvement in pulmonary pressures and exercise capacity. However the role of this reflex in humans is still controversial and has also yet to be evaluated in COPD induced pulmonary hypertension [32].

1.1.1. The right ventriculo-arterial model

1.1.1.1. Right ventricle. The right ventricle (RV) got off to an inauspicious start in the 1940s and 50s when a series of papers showed no significant alterations in the pulmonary arterial or systemic pressures following open ablation of the right heart in a dog model, leading one of the authors to conclude that “a normal, contractile right ventricular wall is not necessary for the maintenance of a normal circulation” [33–35]. Despite this apparent swan song for a significant role of the right ventricle, a paper in 1982 demonstrated that the open pericardial model did not accurately represent the functional haemodynamics of the heart [36]. Goldstein et al. demonstrated that when the right coronary artery was infarcted within an intact pericardium there was a profound and rapid fall in left ventricular pressures due to a fall in left ventricular (LV) preload, equalisation of RV and LV pressures and elevated intrapericardial pressures which did not occur when they repeated their experiment after pericardiectomy. Thus there is a marked ventricular interdependence due to the shared pericardial compartment, shared interventricular septum and the dependence of the left heart preload on the output of the right [37–43].

Recent work has shown the importance of the right heart in health and disease. In health the right ventricle responds to exercise, obesity and traditional cardiovascular risk factors in a manner similar to, but independent of, the left ventricle [44–46]. A decreased RV mass is associated with an increased risk of developing dyspnoea, and an increased RV mass is associated with an increased risk of future congestive cardiac failure and cardiovascular mortality in a healthy population [47,48]. In patients with COPD, right ventricular remodelling is apparent even early in the disease with right ventricular hypertrophy and diastolic dysfunction present in mild and moderate COPD with systolic impairment occurring in severe COPD [12,13]. This has significant implications with right ventricular dysfunction associated with poorer exercise capabilities and increased mortality independent of pulmonary function tests [49,50].

1.1.1.2. Pulmonary artery. There has been a great deal of recent interest in systemic arterial stiffening in COPD due to the mechanistically plausible link this provides between COPD and the excess cardiovascular mortality associated with this condition [51]. In comparison to the systemic arterial circulation there are several key differences in the nature of the vascular tree between that of the pulmonary and systemic circulation. The pulmonary artery is a low pressure, high distensibility system which acts to transform the highly pulsatile right ventricular output into the near steady flow at the capillary level [52]. The distal pulmonary vascular bed is also comprised of highly distensible vessels that, through distension and recruitment of the microvascular bed, are able to accommodate large increases in volume such as during exercise. This response is the opposite of that experienced in the systemic circulation where exercise induces vasoconstriction in the majority of the vascular tree other than the vessels supplying the muscles. This inbuilt reserve means that resting pulmonary arterial pressures will only rise relatively late in a disease process when 60–70% of the bed is obstructed [53]. The peripheral distensibility of the vessels also differs from the systemic circulation where only the proximal arteries act as capacitance vessels, expanding and contracting with each beat of the heart, while the peripheral vessels are responsible for resistance. Due to the dual function of the vessels, there is an inverse relationship between the resistance and capacitance of the pulmonary circulation, with the product of the two (the resistance-compliance time constant) remains the same in both health and disease [54].

The pulmonary arteries and microcirculation have distinct effects on the right ventricular afterload which can be split into two key components – the steady component required to drive and maintain forward flow and the oscillatory component required to overcome the pulsatile component of flow. The steady component
is a function of peripheral vascular resistance whereas the oscillatory component is a function both proximal and distal pulmonary arterial stiffness [55]. Even in the healthy adult, 30% of the right ventricular output is spent on generating pulsations (compared with only 10% in the systemic circulation) [56]. This energy is considered wasted in terms of ventricular power output, but is crucial in acting as a blood reservoir and maintaining steady flow through the pulmonary tree [57]. As the pulmonary artery stiffens the oscillatory component of the workload increases, although remains as a constant of the total energy expenditure of the right ventricle [58,59]. As the artery stiffens it also starts to dilate and become less compliant, and the dilation of this in relation to the aorta has been shown to be a useful clinical marker in COPD, with a PA:aortic ratio>1 an independent predictor of future acute exacerbations, exercise capacity, pulmonary hypertension and mortality [60–63].

The compliance of the pulmonary artery is a key component in decoupling the right ventricle from the pulmonary bed, allowing the right ventricle to work at maximum efficiency and protecting the microcirculation from large pressure gradients [52,64]. Indeed the stiffness of the pulmonary artery is a strong determinant of right ventricular function [65], and increased stiffness causes distal pulmonary arterial endothelial dysfunction and inflammation [66,67]. Increased stiffness is independently associated with reduced functional capacity [68], and higher mortality than the pulmonary artery pressures or pulmonary vascular resistance [69–73]. While vascular distensibility is partly dependent on underlying distending pressures [74,75], multiple studies have shown the intrinsic stiffness of the arterial walls to be increased in pulmonary hypertension independently of these [76–80].

1.1.1.3. Right ventriculo-arterial model. Optimal ventriculo-arterial coupling occurs when there is maximal transference of potential energy from one elastic chamber to another, e.g. from the ventricle to the artery. This is dependent on the elastance — the change in pressure for a given change in volume — of the two chambers [81]. The ventricular elastance (Ees) is a load independent measure of the ventricular contractility combined with the modulating effects of the geometric and structural properties of the ventricle [82]. It relies on measuring the response of the ventricular pressure to increasing volumes (see Fig. 1). The arterial elastance (Ea) is an index incorporating the elements affecting arterial load including pulmonary vascular resistance, arterial compliance, characteristic impedance, and systolic and diastolic time interval [83,84]. The Ea/Ees calculates the extent of ventriculo-arterial coupling. At rest the ventricle and pulmonary artery are coupled so that the right ventricle is working at optimal efficiency which occurs when the stroke work is maximal with minimal oxygen consumption [55,85–87]. This has been shown to occur when Ea is half Ees [87–89]. In exercise this moves towards optimal coupling when there is maximal cardiac efficiency which is where there is maximum flow generation with minimal energy loss (Ea = Ees) [90–92]. Interestingly the optimal values for energy efficiency and cardiac efficiency are similar throughout a variety of studied mammals suggesting it has been conserved throughout mammalian evolution [93,94]. During exercise, arterial stiffness has a progressively and intensity-dependant greater impact on Ea than PVR with the result that Ea increases on exercise despite a fall in PVR in a manner paralleling the rise in arterial stiffness [95–97]. A similar relationship is present in pulmonary hypertension whereby pulmonary stiffness has a 1.2–18 fold greater contribution to right ventricular workload than PVR [74,76,54]. In the systemic circulation, age and hypertension (two known factors associated with increased arterial stiffness) result in an exaggerated increase in Ea during exercise increasing the pulsatile load on the heart and in turn decreasing left ventricular efficiency [90,98]. This exaggerated response secondary to arterial stiffening may explain the rapid rise in mPAP observed in COPD during exercise despite a stable or minimal rise in PVR [18]. Indeed in a study by Hilde et al., an increase in pulmonary arterial stiffness was observed during exercise with a greater contribution from this to changes in mPAP than PVR [3]. Further indirect evidence comes from a study by Kubo et al. which showed the pulmonary arterial wall thickness to be related to exercise pulmonary pressures rather than resting pulmonary pressures, and to correlate highly with change in pressure from rest to exercise [99].

When the Ea increases so that the Ea/Ees is consistently above 0.5 the ventricle adapts to the increased workload by inducing hypertrophy [101]. This increases the Ees thereby returning the ventriculo-arterial system to its most energy efficient state, albeit at a slightly higher energy consumption than previously [102–104]. As Ea continues to rise the right ventricle eventually fails to adapt with a resultant decrease in the Ees and thereby a rapid increase in Ea/Ees indicating uncoupling and reduced myocardial efficiency [87,105].

Fourie et al. demonstrated that myocardial efficiency reached a maximum when the Ea reached 1mmHgm−1 (corresponding to an mPAP of 20 mmHg), while maximum stroke work corresponded to an Ea of 2 mmHgm−1 (corresponding to a MPAP of 30–40 mmHg) [52]. This corresponds with observations that at approximately 40 mmHg the pulmonary artery reaches its maximum dimension and minimal distensibility [78,105,106]. Consistent with this, Stevens et al. demonstrated that in patients with pulmonary hypertension there was a curvilinear relationship between RV function and PA distensibility with marked loss of pulmonary artery distensibility without commensurate loss of ventricular function until only minimal distensibility remained when a rapid decompensation of the right ventricle occurred [76]. A similar curvilinear relationship has also been observed in COPD between pulmonary arterial stiffness and peripheral vascular resistance, with a rapid rise in PVR only occurring after significant stiffening of the pulmonary arteries has occurred [11]. Pulmonary stiffness is increased early in pulmonary hypertension development, and is increased even in those with exercise induced pulmonary hypertension, both in mixed pulmonary arterial hypertension studies and in COPD [3,11,78,106]. This combination of features suggest pulmonary
arterial stiffness as a promising biomarker for detection of early disease and as a potential therapeutic target before end stage arterial remodelling occurs with dire consequences for the right ventricle.

1.1.2. Measuring pulmonary artery stiffness

The stiffness of the pulmonary artery can be quantified using a variety of metrics, with these measuring stiffness locally, regionally or systemically. Table 1 summarises the various methods of measuring arterial stiffness and the common methods for acquiring these. As can be seen from the table the majority of these require knowledge of the arterial pressures to calculate the stiffness. In the arterial circulation this is not a significant issue as the brachial arterial pressures are readily obtained with a sphygmomanometer, as mean BP and diastolic BP are relatively constant throughout the large arteries [107]. However in the pulmonary arteries this provides a significant hurdle as an external measurement of the pressures is not readily available. Despite numerous attempts to quantify pulmonary arterial pressures and vascular resistance using echocardiography, CT and MRI, none of these have yet proven accurate enough to negate the need for invasive measurement with right heart catheterisation [108–115].

1.1.2.1. Right heart catheterisation. Right heart catheterisation can be used to calculate several metrics of arterial stiffness, including capacitance, PWV and elastic modulus. As a potential therapeutic target before end stage arterial stiffness and the common methods for acquiring these. Despite evidence that IPAH has increased arterial stiffness, IPAH patients have not yet been proven to have increased arterial stiffness [109–111]. Table 2 summarises the studies looking at invasive assessment of pulmonary arterial stiffness. Despite its utility, RHC has numerous disincentives including its invasive nature, cost, and exposure to ionising radiation. While the combination of MRI and right heart catheterisation offers catheter guidance without exposure to ionising radiation and simultaneous acquisition of anatomical and pressure measurements, it does not negate the invasive or costly nature of.

Table 1
Measures of arterial stiffness – Calculations, definitions and alternate means of assessment.

| Local | Compliance (mm²/mmHg) | Distensibility (%/mmHg) | Elastic modulus (mmHg/m²) |
|-------|-----------------------|------------------------|--------------------------|
|       | (maxA – minA)/minA X 100 | [(maxA – minA)/PP] X 100 | PP X minA/(maxA – minA) |
|       | Relative change in lumen area during the cardiac cycle | Absolute change in lumen area for a given change in pressure | Slope of the function between distending arterial pressure and arterial distension |

Table 2
Summary of studies looking at invasive measurement of pulmonary arterial stiffness.

| Study | Population | No | Method | Finding |
|-------|------------|----|--------|---------|
| Milnor et al. [118] | Mixed PH | 7 | RHC | Increased impedance in PH |
| Nakayama et al. [119] | Mixed PH | 62 | RHC | Increased augmentation index and earlier inflection time in PH |
| Castlairn et al. [77] | Mixed PH | 14 | RHC | Increased augmentation index and earlier inflection time in PH |
| Mahapatra et al. [70] | Mixed PH | 104 | RHC | Capacitance strongest predictor of mortality in PH. On multivariate analysis, capacitance was the only statistically significant predictor of mortality. |
| Hilde et al. [11] * | COPD | 98 | RHC | PA compliance greatly reduced in COPD Gold 2,3 and 4 |
| Hilde at al [3] * | COPD | 98 | RHC | PA compliance fell with exercise in patients with and without PH, with similar elevations in mPAP during exercise between the two groups. |
| Muthurangu et al. [120] | IPAH | 17 | RHC with MRI | Inverse relationship between compliance and PVRI and mPAP. A fall in compliance was evident in 7/17 following nitric oxide inhalation |
| Kuehne et al. [87] | Mixed | 12 | RHC with MRI | Increased elastic resistance in PH, with resultant ventriculo-arterial uncoupling |
| Kopec et al. [121] | IPAH | 26 | RHC with IVUS | PWV high in IPAH (mean PWV 10 ms-1) with excellent correlation with compliance (β = 0.81) and reasonable correlation with mPAP (β = 0.48) |
| Lau et al., 2012 [79] | IPAH | 8 | RHC with IVUS | Increase in all measure of pulmonary arterial stiffness. Inverse curvilinear relationship between mPAP and compliance and distensibility. No change in PA stiffness following 6 months of bosentan therapy. |
| Rodes-Gabau et al. [72] | IPAH | 20 | RHC with IVUS | Epoprostenol infusion increased pulsatility by 53%. |
| Lau et al., 2014 [122] | IPAH | 5 | RHC with IVUS | High PWV in IPAH (mean PWV 10.6 ms-1) with the reflected backward compression wave carrying 31% of the energy of the forward compression wave |

COPD – chronic obstructive pulmonary disease; CoV – Coefficient of variation; EIPH – Exercise induced pulmonary hypertension; FEV1 – Forced expiratory volume in 1 s; HV – Healthy volunteers; IPAH – Idiopathic pulmonary arterial hypertension; NYHA – New York heart association; PASP – Pulmonary artery systolic pressure; PH – Pulmonary hypertension; PWV – pulse wave velocity; QA – flow by area; TT – transition time; 6MWT – 6 min walking test. * Drawn from the same population.
the study [116,117]. Of the measures of arterial stiffness, only pulsatility and pulse wave velocity can be derived entirely non-invasively.

1.1.2.2. Pulsatility. Multiple studies have shown reduced pulsatility in pulmonary hypertension. [68,69,80,106,123–125]. A single echocardiography study has shown reduced pulmonary artery pulsatility in COPD, which correlated with right ventricular functional parameters [126]. A single abstract using cardiac MR has also described decreasing pulsatility with increasing severity of COPD [127] (Table 3). However, as discussed above, the pulmonary stiffness is dependant not only upon distending pressures, but also upon the intrinsic elasticity of the pulmonary vessel wall, thus a fall in pulmonary pulsatility does not differentiate a fall in pulsatility due to a fall in stroke volume or in distending pressures from that of a rise in arterial stiffness.

1.1.2.3. Pulse wave velocity. Pulse wave velocity (PWV) is the speed at which the pressure wave, generated by ventricular contraction, is transmitted through the arterial tree. This is directly related to vessel wall elasticity, with increased stiffness leading to increased PWV [128]. A reflected pressure wave is present which is generated when the pressure wave is reflected from the termination of the arteries, with alterations in the smallest arteries increasing the size of the reflected wave while large artery stiffening increases the PWV [118]. In health this reflected wave only represents a tiny fraction of the total output energy, and arrives in diastole and reduces preload of the subsequent ventricular contraction [92,118,129,130]. However in pulmonary hypertension this can reach 30% of the forward wave energy, with an increased PWV resulting in the earlier arrival of the reflected wave during systole thereby increasing the afterload of the heart and thus cardiac workload [77,119,122,131–133].

PWV is an established marker of arterial stiffness in the systemic circulation with aortic pulse wave velocity shown to be associated with future cardiovascular events, and to improve risk stratification [134]. Transcutaneous waveform analysis methods are the gold standard for aortic PWV measurement including pressure [135], distension [136], and flow waveform [137]. However a transcutaneous approach is not possible for the pulmonary arteries. While PWV can be measured invasively on right heart catheterisation [118], magnetic resonance imaging is a possible alternative for non-invasive assessment of the pulmonary arteries using flow waveforms [138]. It is performed by the acquisition of ECG gated phase contrast sequences which measure flow through the proximal main pulmonary artery and in the mid right or left pulmonary arteries. A distance can be calculated between the two imaging planes (Fig. 2), and the pulse wave timed from when it leaves the main pulmonary artery until it arrives in branch pulmonary arteries thus allowing a speed between the two points to be generated [138]. MRI derived pulse wave velocity has been previously validated against both invasive and non-invasive techniques in the aorta [139–141]. Several studies have shown this to be a feasible and reproducible technique in the pulmonary arteries in healthy volunteers [138,142], with the observed pulse wave velocity of 1.96–2.3 ms⁻¹ similar to that obtained invasively [118,129]. Pulse wave velocity is raised in pulmonary hypertension on both invasive and MRI assessment (See Table 2) [121,143]. To date there have been no studies assessing pulmonary PWV in COPD.

### Table 3

Summary of studies looking at non-invasive measurement of pulmonary arterial stiffness.

| Study                  | Population | No | Method | Finding                                                                                                                                 |
|------------------------|------------|----|--------|----------------------------------------------------------------------------------------------------------------------------------------|
| Bogren et al. [159] b  | Mixed PH   | 4  | MRI    | Pulsatility 23% in HV and 8% in PH                                                                                                       |
| Paz et al. [160]       | HV         | 9  | No     | No difference in pulsatility between the main pulmonary artery, right pulmonary artery and left pulmonary arteries                       |
| Gan et al. [69]        | Suspected PH | 70 | MRI    | Right pulmonary artery pulsatility showed a curvilinear relationship with mortality. Pulsatility <16%                                    |
| Jardim et al. [125] b | IPAH       | 19 | MRI    | Pulsatility predicts non-responders to acute vasodilator testing with 100% sens and 56% spec.                                          |
| Sanz et al. [124] a    | Suspected PH | 59 | MRI    | Pulsatility 41% in non-PH and 17.4% in PH. No difference in pulsatility between different causes of PH.                                 |
| Sanz et al. [78] a     | Suspected PH | 94 | MRI    | No difference in pulsatility between group without PH and EIPH. Pulsatility <40% predicted PH with 93% sens. and 63% spec.         |
| Kang et al. [68]       | Mixed PH   | 35 | MRI    | Pulsatility correlated with 6MWT (R² = 0.61, p < 0.001)<20% pulsatility predicted poor function (6MWT <400m) with 82% sens. and 94% spec. |
| Stevens et al. [76] a  | Suspected PH | 124 | MRI    | Pulsatility correlates with right ventricular function                                                                                 |
| Stevens et al. [161]   | Suspected PH | 43 | MRI    | Pulsatility correlated with exercise capacity while RHC pressures did not.                                                             |
| Swift et al. [106]     | Suspected PH | 134 | MRI    | Pulsatility elevated even in very mild elevations in PVR. Pulsatility predicted mortality.                                         |
| Revel et al. [162] b   | Suspected PH | 45 | CT     | Pulsatility of 16.5% predicted PH with sens 86% and spec 96%.                                                                         |
| Pasierski et al. [80]  | Suspected PH | 19 | Echo   | Pulsatility reduced in pulmonary hypertension with a linear relationship between pulsatility and PASP                                |
| Mahapatra et al. [71]  | Suspected PH | 54 | Echo   | Capacitance was the strongest predictor of mortality including invasive pressure measurements                                          |
| Ertan et al. [126]     | COPD       | 54 | MRI    | Right pulmonary artery pulsatility reduced in COPD patients, with significant differences between NYHA functional classes.        |
| Liu et al. [127]       | COPD       | 135 | MRI    | Pulsatility falls with increasing severity of COPD, with a positive association with predicted FEVI and inversely correlated with Thymophsena |
| PWV                    |            |    |        | PWV 1.96 ± 0.27 with high intra-scan and inter-scan reproducibility (5.5% and ~10.9% respectively)                                    |
| Peng et al. [142]      | HV         | 17 | MRI    | No significant difference in PWV using the left or right pulmonary arteries. COV 12% for both intra and inter-observer assessment.     |
| Bradlow et al. [138]   | HV         | 10 | MRI    | PWV raised in pulmonary hypertension. Comparable measurements between TT and QA methods.                                            |

COPD — chronic obstructive pulmonary disease; CoV — Coefficient of variation; EIPH — Exercise induced pulmonary hypertension; FEVI — Forced expiratory volume in 1 s; HV — Healthy volunteers; IPAH — Idiopathic pulmonary arterial hypertension; NYHA — New York heart association; PASP — Pulmonary artery systolic pressure; PH — Pulmonary hypertension; PWV — pulse wave velocity; QA — flow by area; TT — transition time; 6MWT — 6 min walking test.

a Different calculation for % pulsatility so not directly comparable to other studies.

b Drawn from the same population.
Given the greater impact of pulmonary stiffness on remodelling, drugs to target and ameliorate this process may be a novel route to target. Due to the relatively recent identification of the importance of pulmonary arterial stiffness in right ventricular remodelling, there have been relatively few studies targeted at its treatment. Despite this there are several studies suggestive of promising avenues for further exploration.

Statins have been proposed as a route to reduce systemic arterial stiffness [149], although a meta-analysis showed mixed response with two studies showing improvement, one showing no change and another showing progression of stiffening [150]. Statins in guinea pigs and mice with emphysema have been shown to reverse arterial remodelling and halt the formation of emphysema [151,152]. Indirect evidence of the benefits from statins in COPD related pulmonary hypertension come from observational studies showing lower pulmonary arterial pressures in patients on statins prior to right heart catheterisation [153]. Furthermore a study on pulmonary arterial stiffness showed that other than mPAP, the only other factors independently associated with pulmonary arterial stiffness was LDL cholesterol and BMI [121]. Statins are also associated with increased exercise capacity and reduced mortality in COPD [154–156], however due to the observational nature of these studies the underpinning mechanisms are still in debate [157,158].

Xanthine oxidase inhibitors have been shown to improve endothelial function and arterial stiffness in the systemic circulation [163–167]. They have also been shown to reduce endothelial dysfunction induced by smoking and obstructive sleep apnoea [168–170] – a condition similar to COPD in its effects of intermittent hypoxia [171]. Additionally allopurinol inhibits hypoxia induced pulmonary vasoconstriction, pulmonary hypertension, endothelial dysfunction and vascular remodelling in hypoxic animal models of pulmonary hypertension [172–176]. It has been shown to reduce airway reactive nitrogen species production in COPD, however its effects on smoking induced pulmonary vascular damage has not been assessed [177].

As with xanthine oxidase inhibitors, mineralocorticoid receptor antagonists have been shown to improve systemic endothelial function and arterial stiffness [178–180]. In 2 separate mouse models of pulmonary hypertension, mineralocorticoid receptor antagonists prevented or reversed adverse pulmonary vascular remodelling with improved pulmonary vascular resistance, pulmonary artery pressure, and remodelling of the right ventricle [181]. A group in Bethesda, USA are currently recruiting patients with pulmonary hypertension without right heart failure to evaluate its efficacy in humans in modulating pulmonary vascular remodelling [182]. Its use in COPD has not currently been assessed.

Long term oxygen therapy improves survival in severe COPD and reduces pulmonary arterial pressures and vascular resistance while improving cardiac output [6,183]. It has also been shown to reduce peripheral arterial stiffness in COPD, however its effects on the pulmonary arterial stiffness has not been evaluated [184].

There are also several new classes of pharmaceutical agents currently being designed which specifically target the processes causing arterial stiffening. Currently these are all being targeted at systemic vascular remodelling and are in the pre-clinical stages, however should they prove successful at preventing or reversing systemic arterial remodelling they would be promising agents for evaluation in pulmonary remodelling. The most promising of these are TGF-B1 antagonists, and drugs targeting the advanced glycation end products (AGEs) [185], TGF-B1 is responsible for extracellular matrix remodelling and vascular fibrosis in chronic inflammatory conditions, whilst AGE form irreversible cross-links with collagen and elastin, reducing the elasticity of the arterial wall [185].

2. Conclusions

Pulmonary arterial stiffness holds a crucial role in right ventricular dysfunction in pulmonary hypertension, and demonstrates promise as a useful biomarker in the development of this disease. Early work shows similar promise in COPD, and further work is warranted to explore this promising new area.

Acknowledgements: Funding, disclosures

JRWM is supported by the Wellcome Trust through the Scottish Translational Medicine and Therapeutics Initiative (Grant no. WT 085664) in the form of a Clinical Research Fellowship. The funder had no role in study design, the collection, analysis, and interpretation of data; in the writing of the manuscript; nor in the decision to submit the manuscript for publication.

References

[1] A. Hyduk, J.B. Croft, C. Ayala, K. Zheng, Z.-J. Zheng, G.A. Mensah, Pulmonary hypertension surveillance—United States, 1980-2002, MMWR Surveill. Summ. 54 (2005) 1–28.
J.R. Weir–McCall et al. / Respiratory Medicine 109 (2015) 1381–1390

28. B.G. Baylen, G.C. Emmanouilides, C.E. Juratsch, Y. Yoshida, W.J. French, J.M. Criley, Main pulmonary artery distention: a potential mechanism for acute pulmonary hypertension in the human newborn infant. J. Pediatr. 96 (1980) 540–544.

29. C.E. Juratsch, J.A. Jengo, J. Castagna, M.M. Laks, Experimental pulmonary hypertension produced by surgical and chemical denervation of the pulmonary vasculature, Chest 77 (1980) 525–530.

30. J. Osorio, M. Sussex, Reflex changes on the pulmonary and systemic pressures elicited by injection of baroreceptors in the pulmonary artery, Circ. Res. 10 (1962) 664–667.

31. S.-L. Chen, F.-F. Zhang, J. Xu, D.-J. Xie, L. Zhou, T. Nguyen, et al., Pulmonary artery denervation to treat pulmonary arterial hypertension: the single-center, prospective, open-label, randomized, controlled pilot study for pulmonary artery denervation treatment for pulmonary arterial hypertension), J. Am. Coll. Cardiol. 62 (2010) 1192–1190.

32. N. Galie, A. Manes, New treatment strategies for pulmonary arterial hypertension: hopes or hype? J. Am. Coll. Cardiol. 62 (2013) 1101–1102.

33. I. Starr, W.A. Jeffers Jr., RHM, The absence of conspicuous increments of venous pressure after severe damage to the right ventricle of the dog, with a discussion of the relation between clinical congestive failure and heart disease. Am. Heart J. 26 (1943) 291–301.

34. A.C.P. Bakos, The question of the function of the right ventricular myocardiun: an experimental study, Circulation 1 (1950) 724–732.

35. A. Kagan, Dynamic responses of the right ventricle following extensive myocardial damage. J. Clin. Invest. 45 (1966) 461–483.

36. J.A. Goldstein, G.J. Vlahakes, E.D. Verrier, N.B. Schiller, J.V. Tyberg, T.A. Ports, I. Starr, W.A. Jeffers Jr., RHM, The absence of conspicuous increments of venous pressure after severe damage to the right ventricle of the dog, with a discussion of the relation between clinical congestive failure and heart disease. Am. Heart J. 26 (1943) 291–301.

37. J.A. Goldstein, G.J. Vlahakes, E.D. Verrier, N.B. Schiller, J.V. Tyberg, T.A. Ports, I. Starr, W.A. Jeffers Jr., RHM, The absence of conspicuous increments of venous pressure after severe damage to the right ventricle of the dog, with a discussion of the relation between clinical congestive failure and heart disease. Am. Heart J. 26 (1943) 291–301.

38. A. Vonk-Noordegraaf, J.T. Marcus, C.T. Gan, A. Boonstra, P.E. Postmus, Early changes of cardiac structure and function in COPD patients with mild hypoxemia, Chest 127 (2005) 1988–1993.

39. Y. Gao, X. Du, W. Qin, K. Li, Assessment of the right ventricular function in patients with chronic obstructive pulmonary disease using MRI, Acta Radiol. 48 (2013) 1031.

40. M. Oswald-Mammosser, E. Weitzenblum, E. Quoix, G. Moser, A. Chaouat, C. Ducolone, R. Mirhom, J. Rasaholinjanahary, E. Weitzenblum, A. Ducolone, R. Mirhom, J. Rasaholinjanahary, M. Ehrhart, Prognostic value of pulmonary artery pressure in chronic obstructive pulmonary disease, Thorax 36 (1981) 752–758.

41. M.J. Cuttica, R. Kalhan, O.A. Shlobin, S. Ahmad, M. Gladwin, R.F. Machado, et al., Pulmonary arterial hypertension in COPD: epidemiology, significance, and management: pulmonary vascular disease: the global perspective, Chest 137 (2010) 395–515.

42. R. Kessler, M. Faller, E. Weitzenblum, A. Chauvat, A. Aytou, A. Ducolone, et al., ‘Terrestrial history’ of pulmonary hypertension in a series of 131 patients with chronic obstructive lung disease, Am. J. Respir. Crit. Care Med. 164 (2001) 219–224.

43. M. Oswald-Mammosser, E. Weitzenblum, E. Quoix, G. Moser, A. Chaouat, C. Ducolone, R. Mirhom, J. Rasaholinjanahary, M. Ehrhart, Prognostic value of pulmonary artery pressure in chronic obstructive pulmonary disease, Thorax 36 (1981) 752–758.

44. I. Skjørten, J.M. Hilde, M.N. Melsom, V. Hansteen, K. Steine, S. Humerfelt, C.C. Christensen, M.S. Ryg, A. Edvardsen, O.H. Skjønsberg, Relationship between pulmonary vascular structure and function in the guinea pig, Eur. Respir. J. 17 (2001) 711–717.

45. H. Chahal, R.L. McClelland, H. Tandri, A. Jain, E.B. Turkbey, W.G. Hundley, et al., Right ventricular dysfunction and remodeling in chronic obstructive pulmonary disease without pulmonary hypertension, J. Am. Coll. Cardiol. 62 (2013) 1103–1111.

46. A. Vonk-Noordegraaf, J.T. Marcus, C.T. Gan, A. Boonstra, P.E. Postmus, Inter-ventricular mechanical asynchrony due to right ventricular pressure overload in patients with chronic obstructive pulmonary disease: an important role in impaired right ventricular filling, Chest 128 (2005) 6285–6305.

47. J.T. Marcus, C.T.-J. Gan, J.J.M. Zwanenburg, A. Boonstra, C.P. Allaart, M.W.J. Götte, et al., Inter-ventricular mechanical asynchrony in pulmonary arterial hypertension: Right delay in peak shortening is related to right ventricular overload and left ventricular underfilling, J. Am. Coll. Cardiol. 51 (2008) 750–757.

48. A. Vonk-Noordegraaf, J.T. Marcus, B. Roseboom, P.E. Postmus, T.J. Faes, P.M. de Vries, The effect of right ventricular hypertrophy on left ventricular ejection fraction in pulmonary embolism, Chest 112 (1997) 640–645.

49. M.L. Shehata, A.A. Harouni, J. Skrok, T.A. Basha, D. Boyle, N. Lechtzin, et al., Regional and global biventricular function in pulmonary arterial hypertension: a cardiac MR imaging study, Radiology 266 (2013) 114–122.

50. M. Hardzyjenka, M.E. Campian, H.J. Reesink, S. Surie, B.J. Bouma, M. Groenink, et al., Right ventricular failure following chronic pressure overload is associated with reduction in left ventricular mass: evidence for atrophic right ventricular failure, J. Am. Coll. Cardiol. 57 (2011) 617–627.

51. A. Boussuges, C. Pinet, F. Molenat, H. Burnet, P. Ambrosi, M. Badier, et al., Left atrial and ventricular filling in chronic obstructive pulmonary disease: An echocardiographic and Doppler study, Am. J. Respir. Crit. Care Med. 162 (2000) 670–675.

52. C.P. Aaron, H. Tandri, R.G. Barr, W.C. Johnson, E. Bagiella, H. Chahal, et al., Relation of cardiovascular risk factors to right ventricular structure and function. The MESA-right ventricle study, Am. J. Respir. Crit. Care Med. 183 (2011) 395–404.

53. H. Chahal, C. Johnson, H. Tandri, A. Jain, W.G. Hundley, R.G. Barr, et al., Relation of cardiovascular risk factors to right ventricular structure and function as determined by magnetic resonance imaging (results from the multi-ethnic study of atherosclerosis), Am. J. Cardiol. 106 (2010) 110–116.

54. H. Chahal, R.L. McClelland, H. Tandri, A. Jain, E.B. Turkbey, W.G. Hundley, et al., Obesity and right ventricular structure and function: the MESA-right ventricle study, Chest 141 (2012) 388–395.

55. M.R. Kaufmann, R.G. Barr, J.A.C. Lima, A. Praestgaard, A. Jain, H. Tandri, et al., Right ventricular morphology and the onset of dyspnea: the MESA-right ventricle study, PLoS One 8 (2013) e56826.

56. S.M. Kawut, R.G. Barr, J.A.C. Lima, A. Praestgaard, W.C. Johnson, H. Chahal, et al., Right ventricular structure is associated with the risk of heart failure and cardiovascular death: the multi-ethnic study of atherosclerosis (MESA)–right ventricle study, Circulation 126 (2012) 1681–1688.

57. M.J. Cuttica, S.J. Shah, S.R. Rosenberg, R. Orr, L. Beussink, J.E. Dematte, et al., Right heart structure and function is independently associated with exercise capacity in non-severe COPD, PLoS One 6 (2011) e29069.

58. M.L. Burgess, N. Mogulkoc, R.J. Bright-Thomass, P. Bishop, J.J. Egan, S.G. Ray, Comparison of echocardiographic markers of right ventricular function in determining prognosis in chronic pulmonary disease, J. Am. Soc. Echo-cardiogr. 15 (2002) 633–639.

59. I. Vövodznev, R. Tamisier, J.-P. Baguet, J.C. Borel, P. Levy, J.-L. Périn, Arterial stiffness in COPD, Chest 145 (2014) 861–875.
[105] J. Sanz, A. García-Alvarez, I. Fernández-Friera, A. Nair, J.G. Mirelis, S.T. Sawit, et al., Right ventricular-arterial coupling in pulmonary hypertension: a magnetic resonance study. Heart 98 (2012) 238–243.

[106] A.J. Swift, S. Rajaram, R. Condliffe, D. Capener, J. Hardman, C. Elliot, et al., Pulmonary artery relative area change detects mild elevations in pulmonary vascular resistance and predicts adverse outcome in pulmonary hypertension. Circulation 120 (2010) 571–580.

[107] E.J. Kroeker, E.H. Wood, Comparison of simultaneously recorded central and peripheral arterial pressure pulses during rest, exercise and tilted position in man, Circ. Res. 3 (1955) 623–632.

[108] E. Laffon, F. Laurent, V. Bernard, L. De Boucaud, D. Ducassou, R. Maïret, et al., Noninvasive assessment of pulmonary arterial hypertension by MR phase-mapping method, J. Appl. Physiol. 90 (2001) 2197–2202.

[109] G. Reiter, U. Reiter, G. Kovacs, B. Kainz, K. Schmidt, R. Maier, et al., Magnetic resonance-derived intravascular blood flow patterns in the main pulmonary artery as a marker of pulmonary hypertension and a measure of elevated mean pulmonary arterial pressure, Circ. Cardiovasc Imaging 1 (2008) 23–30.

[110] T.S. Saha, J. Foster, M. Coburn, M. Cowan, A.J. Peacock, Ventricular mass index using magnetic resonance imaging accurately estimates pulmonary artery pressure, Eur. Respir. J. 20 (2002) 1519–1524.

[111] A.J. Swift, S. Rajaram, J. Hardman, C. Hill, C. Davies, T.W. Sproston, et al., Noninvasive estimation of PA pressure, flow, and resistance with CMR imaging: derivation and prospective validation study from the ASPIRE registry, JACC Cardiovascular Imaging 6 (2013) 1036–1047.

[112] R. Amyas, A. Benetos, J. Topouchian, P. Laurent, B. Pannier, A.M. Bislic, et al., Assessment of arterial stiffness by automatic pulse wave velocity measurement. Validation and clinical application studies, Hypertension 26 (1995) 485–490.

[113] R.J. Roeleveld, J.T. Marcus, A. Boonstra, P.E. Postmus, K.M. Marques, et al., Chronic obstructive pulmonary disease (COPD) is associated with pulmonary arterial hypertension: noninvasive detection with phase-contrast magnetic resonance, J. Magn. Reson Imaging 22 (2005) 67–72.

[114] M. Nogami, Y. Ohno, H. Koyama, A. Kono, D. Takenaka, T. Kataoka, et al., Utility of phase contrast MR imaging for assessment of pulmonary flow and pressure estimation in patients with pulmonary hypertension: comparison with right heart catheterization and echocardiography, J. Magn. Reson Imaging 30 (2009) 973–980.

[115] M.R. Fisher, P.R. Forfa, E. Chamera, T. Housten-Harris, H.C. Champion, R.E. Girgi, et al., Accuracy of Doppler echocardiography in the hemodynamic assessment of pulmonary hypertension, Am. J. Respir. Crit. Care Med. 179 (2009) 615–621.

[116] M. Pienn, G. Kovacs, M. Tscherner, A. Avian, T.R. Johnson, P. Kullnig, et al., Non-invasive determination of pulmonary hypertension with dynamic contrast-enhanced computed tomography: a pilot study, Eur. Radiol. 24 (2014) 406–412.

[117] V. Muthurangan, A. Taylor, R. Andriantsimianvona, S. Hegde, M.E. Miquel, R. Tulloch, et al., Novel method of quantifying pulmonary vascular resistance by use of simultaneous invasive pressure monitoring and phase-contrast magnetic resonance flow, Circulation 110 (2004) 826–834.

[118] T. Kuehne, S. Yilmaz, I. Schulze-Neick, E. Wellinboer, P. Ewert, E. Nagel, et al., Magnetic resonance imaging guided catheterisation for assessment of pulmonary vascular resistance: in vivo validation and clinical application in patients with pulmonary hypertension, Heart 95 (2009) 1064–1069.

[119] W.R. Milnor, C.R. Conti, K.B. Lewis, M.F. O’Rourke, Pulmonary arterial pulse wave velocity and impedance in man, Circ. Res. 25 (1969) 637–649.

[120] S. Nakayama, N. Nakamishi, T. Hayashi, N. Nagaya, F. Sakamaki, S. Sato, et al., Pulmonary artery pressure reflection for diagnosis of early primary pulmonary hypertension and chronic pulmonary thromboembolism, J. Am. Coll. Cardiol. 38 (2001) 214–218.

[121] V. Muthurangan, D. Atkinson, M. Sermesant, M.E. Miquel, S. Hegde, R. Tulloch, et al., Measurement of total pulmonary arterial compliance using invasive pressure monitoring and MR flow quantification during MR-guided cardiac catheterization, Am. J. Physiol. Heart Circ. Physiol. 289 (2005) H1301–H1306.

[122] G. Kopeć, D. Moertl, P. Jankowski, A. Tyrka, B. Sobie, P. Ewert, et al., Improved right ventricular-pulmonary arterial pressure coupling in patients with COPD, Eur. Respir. J. 38 (2011) 982–992.

[123] E.M.T. Lau, D. Axelsson, N. Dwyer, Y. Yu, M.K. Ng, D.S. Celermajer, Assessment of ventriculo-arterial interaction in pulmonary arterial hypertension using wave intensity analysis, Eur. Respir. J. 43 (2014) 1804–1807.

[124] S. Moral, L. Fernández-Friera, G. Stevens, G. Guzman, A. García-Alvarez, A. Piqué, et al., New index x improves detection of pulmonary hypertension in comparison with other cardiac magnetic resonance indices, Int. J. Cardiol. 161 (2012) 25–30.

[125] J. Sanz, P. Kuschin, T. Rius, R. Salguero, R. Sulaica, A.J. Einstein, et al., Pulmonary arterial hypertension: noninvasive detection with phase-contrast MR imaging, Radiology 243 (2007) 70–79.

[126] C. Jardim, C.E. Rochitte, M. Humbert, G. Rubenfeld, D. Jasinowodolinski, S. Moral, L. Fernández-Friera, A.R. Goudie, B.J. Lipworth, P.J. Hopkinson, L. Wei, A.D. Struthers, Tadala et al., Pulmonary artery distensibility in pulmonary arterial hypertension: noninvasive detection with phase-contrast magnetic resonance, J. Magn. Reson Imaging 25 (2007) 974–981.

[127] J.M. Westenberg, E.P. van Poeleg, P. Steendijk, H.B. Crotzheus, J.W. Jukema, A. De Roos, Bramwell-Hill modeling for local aortic pulse wave velocity estimation: a cross-sectional study with velocity-encoded pelvic magnetic resonance imaging and invasive pressure assessment, J. Cardiovasc Magn. Reson 14 (2012) 2.

[128] L. Joly, C. Perret-Guillaume, A. Kearney-Schwartz, P. Salvi, D. Mandy, P.-Y. Marie, et al., Pulse wave velocity assessment by external noninvasive devices and phase-contrast magnetic resonance imaging in the obese, Hypertension 54 (2009) 421–426.

[129] A. Dogu, N. Kachenoura, F. Frouin, M. Lefort, A. De Cesare, E. Mousseaux, et al., Consistency of aortic distensibility and pulse wave velocity estimates with respect to the Bramwell-Hill theoretical model: a cardiovascular magnetic resonance study, J. Cardiovasc Magn. Reson 13 (2011) 11.

[130] H.-H. Peng, W.-H. Chung, H.-Y. Yu, W.-J. Tseng, Estimation of pulse wave velocity in main pulmonary artery by magnetic resonance imaging: preliminary investigation, J. Magn. Reson Imaging 24 (2006) 1303–1310.

[131] E.-S. Ibrahim, J.M. Shaffer, R.D. White, Assessment of pulmonary artery stiffness using velocity-encoding magnetic resonance imaging: evaluation of the MACHINES, Magn. Reson. Imaging 29 (2011) 966–974.

[132] I. Blanco, E. Gimeno, P.A. Munoz, S. Pizarro, C. Gistau, R. Rodriguez-Roisin, et al., Hemodynamic and gas exchange effects of sildenafil in patients with chronic obstructive pulmonary disease and pulmonary hypertension, Am. J. Respir. Crit. Care Med. 181 (2010) 270–278.

[133] I. Blanco, S. Santos, J. Gea, R. Güell, F. Torres, E. Gimeno-Santos, et al., Sildenafil to improve respiratory rehabilitation outcomes in COPD: a controlled trial, Eur. Respir. J. 31 (2008) 912–921.

[134] M. Stolz, H. Rauch, A. Linka, M. Di Valentino, A. Meyer, M. Badeau, et al., Improved right ventricular-pulmonary arterial coupling in patients with COPD, Lancet Respir. Med. 2 (2014) 1390–1391.

[135] E.R. Cizik, A. Koyuncu, F. Ozcakar, A. Yilmaz, N. Haldun, H. Yilmaz, et al., Venous return in the supine position: a comparison of three different magnetic resonance imaging techniques, J. Cardiovasc Magn. Reson. 15 (2013) 336.
